Advantages of Enzyme Immuno Assay After Blotting in Blood Stain Grouping. Application to the Gc Subtypes

1986 ◽  
pp. 382-385 ◽  
Author(s):  
Bernadette M. Hoste
Keyword(s):  
Immuno Assay ◽  
Enzyme Immuno Assay

Application of EM to differentiate herpes virus from pox virus in genital specimens

1994 ◽  
Vol 52 ◽  
pp. 262-263
Author(s):  
K. Rekrut ◽  
K. Schleuter
Keyword(s):  
Tissue Culture ◽  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Fresh Tissue ◽  
Culture Cells ◽  
Viral Transport ◽  
Carbon Coated ◽  
Immuno Assay ◽  
Simplex Virus ◽  
Enzyme Immuno Assay

Confirmation of herpes simplex virus (HSV) from genital lesions of obstetrical (OB) patients may affect both the management of the delivery and of the neonate.(l,2) During 1992 and 1993, 4,450 genital specimens from OB patients were submitted in viral transport media for herpes culture. The specimens were inoculated into MRC-5, Vero, and A-549 tissue culture tubes, incubated, and examined daily for 7 days for cytopathic effect (CPE). The original specimens were frozen at −70° C until final reports were issued. Culture tubes with CPE were tested by the Dupont Herpchek enzyme immuno assay (EIA) to confirm the presence of herpes simplex virus (HSV). (3,4) 170 OB patient specimens were positive by culture and confirmed by EIA.There were also 63 cultures exhibiting CPE ressembling HSV which were negative by EIA testing, which failed to pass in fresh tissue culture cells or progress to more enhanced CPE in culture. These original specimens were screened by electron microscopy after direct ultracentrifugation employing the Beckman airfuge with the EM 90 rotor on to formvar carbon-coated 300 mesh copper grids and negatively stained with 2% PTA.

11-dehydro-thromboxane B2 enzyme immuno assay, a suitable screening assay for aspirin use?

2001 ◽  
Vol 120 (5) ◽  
pp. A596-A596
Author(s):  
M LEERDAM ◽  
F HUDIG ◽  
W ROOIJEN ◽  
E SLAATS ◽  
A GERAEDTS ◽  
...  
Keyword(s):  
Thromboxane B2 ◽  
Screening Assay ◽  
Immuno Assay ◽  
Enzyme Immuno Assay

scholarly journals Measurement of toxoplasma IgM by a microparticle capture enzyme immuno-assay

1993 ◽  
Vol 38 (1) ◽  
pp. 34-37 ◽  
Author(s):  
A. V. Hall ◽  
J. D. Johnson ◽  
P. J. Stevens ◽  
N. E. Renton ◽  
R. E. Holliman
Keyword(s):  
Immuno Assay ◽  
Enzyme Immuno Assay

Increased Serum Level of 8-Hydroxy-2’-Deoxyguanosine may be an Indication of Pesticides Induced DNA Damage among Indian Farmers

2021 ◽  
Vol 11 (7) ◽  
pp. 89-98
Author(s):  
Arun Pandiyan ◽  
Summaiya Lari ◽  
Sudip Ghosh
Keyword(s):  
Dna Damage ◽  
Oxidative Dna Damage ◽  
Serum Levels ◽  
Study Data ◽  
Exposed Group ◽  
Healthy Controls ◽  
Data Assessment ◽  
Pesticides Exposure ◽  
Immuno Assay ◽  
Enzyme Immuno Assay

The aim of the present hospital based study is to assess the serum levels of 8-hydroxy-2’-deoxyguanosine (8-OHdG) among 152 subjects. A total of 152 subjects, categorized into 3 groups: (i) pesticides exposed group (N=60), (ii) pesticide un-exposed group (N=42) and (iii) healthy controls group (N=50) were recruited for the study following the inclusion and exclusion criteria. The blood was drawn from the eligible subjects and Enzyme Immuno Assay (EIA) was performed to assess the 8-OHdG levels in serum. Appropriate statistical methods were used to analyse the study data. Assessment showed that pesticides exposed group has higher levels of serum 8-OHdG as compared to un-exposed group and healthy controls. Age and duration of exposure had an impact on the levels of serum 8-OHdG.The higher serum levels of 8-OHdG may be a marker for pesticides-induced oxidative DNA damage. Key words: pesticides; exposure; oxidative stress; 8-hydroxy-2’-deoxyguanosine (8-OHdG).

An Enzyme Immuno Assay for the Detection of Basic Myelin Protein and Antibodies to BMP in CSF

1983 ◽  
pp. 227-229
Author(s):  
G.J. VAN KAMP ◽  
J.C. KOETSIER ◽  
L. LUYENDIJK ◽  
J. O. MISPELBLOM BEIJER ◽  
C.L. VERWEY
Keyword(s):  
Myelin Protein ◽  
Immuno Assay ◽  
Enzyme Immuno Assay ◽  
Basic Myelin Protein

EORTC External Quality Assurance Program for ER and PgR Measurements: Trial 1998/1999

2000 ◽  
Vol 15 (1) ◽  
pp. 62-69 ◽  
Author(s):  
C.G.J. Sweep ◽  
J. Geurts-Moespot
Keyword(s):  
Binding Assay ◽  
Steroid Receptor ◽  
Quality Assurance Program ◽  
External Quality ◽  
Essential Requirement ◽  
The Mean ◽  
Immuno Assay ◽  
Receptor Assays ◽  
Enzyme Immuno Assay

Steroid receptor assays have clinical relevance in selecting women who would benefit from endocrine intervention. As the degree of benefit from endocrine therapy is directly related to the quantity of receptor present in the tumour, the quality of the steroid receptor assays is important. Moreover, since patients entered in multi-centre trials often include stratification based on the receptor status, receptor assays should be comparable between different institutes. ER- and PgR-assays have been evaluated in quality assessment studies for almost 20 years by the EORTC Receptor and Biomarker Study Group. During the QA trial 1998/1999 results were reported by 42 participants performing the Ligand Binding Assay (LBA) and by 39 participants using the Enzyme Immuno-Assay (EIA) kit. Each participant received a set of 12 QA vials to be analysed two at a time at two-monthly intervals. The between-laboratory CVs of ER LBA and EIA amounted to 40–50%. For PgR the between-lab CVs for the EIA method are lower as compared with LBA but still are approx. 30%. Notwithstanding the high deviation in reported values and the high between-lab CVs, the consistency of the participants over the year is acceptable, which pave the way for calibration. Indeed, after normalization of assay results the mean between-lab CVs dropped to 11% for ER LBA, 14% for ER EIA, 9% for PgR LBA and 11% for PgR EIA. Such a reduction of between-laboratory CVs is an essential requirement for the use of steroid receptor data in multicentre clinical studies.

Increase of Thrombin-Antithrombin III (TAT) Complex Plasma Levels in Thromboembolic Diseases during Thrombolysis

1987 ◽  
Author(s):  
R Seitz ◽  
G Pratorius ◽  
R Blanke ◽  
B B Strauer
Keyword(s):  
Thrombolytic Therapy ◽  
Plasma Levels ◽  
Vein Thrombosis ◽  
Complex Plasma ◽  
In Vitro Effects ◽  
Immuno Assay ◽  
Enzyme Immuno Assay ◽  
Deep Vein

Recently an enzyme immuno assay of thrombin-antithrombinlll complex (TAT) plasma levels was developed by PELZER et al. (Thromb. Haemost. 54:24,1985). This test appears to be useful in the detection of intravasal thrombin generation, since all of 17 patients (pts.) with pulmonary embolism and 15 of 16 pts. with deep vein thrombosis (DVT) showed elevated values above 3 ng/ml.In 9 pts. with acute myocardial infarction (AMI) the TAT levels increased significantly (p 0.001) 3 to 6 hours after thrombolytic therapy with 1.5 million units streptokinase (SK) over 30 minutes. A concomitant increase of fibrinopeptide A (FPA) levels (p=0.048) was observed. In contrast, 8 AMI pts. treated with heparin showed an insignificant increase of TAT and FPA. In 7 DVT pts. the TAT levels rose significantly (p 0.001) within 6 hours after start of urokinase (UK) infusion, while the FPA levels were enhanced prior to treatment and showed no further increase.In order to assess the in vitro effects of SK and UK on TAT levels, clots obtained by recalcification of citrated plasma were incubated in heparin (2 units/ml) plasma. An increase of TAT occurred after addition of SK or UK, which was less pronounced when the clots were rinsed extensivly or squeezed before incubation. When SK or UK were added to plasma in the absence of a clot, still a small increase of TAT occurred which was absent in saline controls.The data suggest that SK and UK action is associated with the generation of TAT complexes. In vivo, thrombin or thromboplastic material might be released by enhanced "wash out" from the recanalized coronary artery or from the reperfused in-farcted myocardium. Thrombin might also be released from binding sites on fibrin clots or fibrinogen. It is conceivable that these findings contribute to the understanding of reocclusion of infarct vessels after thrombolytic therapy. This points to the importance of careful anticoagulation in patients receiving thrombolytic therapy.

Sign in / Sign up

Export Citation Format

Share Document